BioLight Life registers $10 million of stock for initial public sale

Bookrunners Feltl and Rodman & Renshaw will assist with offering

By Devika Patel

Knoxville, Tenn., Feb. 10 – BioLight Life Sciences Ltd. will price its initial public offering of ordinary shares with a 45-day greenshoe, according to a Form F-1 filed Wednesday with the Securities and Exchange Commission. The company has registered up to $10 million of stock.

Feltl and Co. and Rodman & Renshaw are the bookrunners.

Proceeds will be used to develop and commercialize products and product candidates and expand the company’s product pipeline, for research and development, for obtaining regulatory clearances and approvals, for establishing marketing capabilities and the company’s sales force, for working capital and for general corporate purposes.

The ophthalmic company is based in Tel Aviv. The company intends to list its stock on the Nasdaq under the symbol “BOLT.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.